Jenburkt (JENBURPH) | Financial Analysis & Statements
Jenburkt Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
355.3M
Gross Profit
290.1M
81.65%
Operating Income
82.3M
23.18%
Net Income
77.9M
21.93%
EPS (Diluted)
₹17.66
Balance Sheet Metrics
Total Assets
2.0B
Total Liabilities
244.1M
Shareholders Equity
1.7B
Debt to Equity
0.14
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Jenburkt Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.5B | 1.4B | 1.4B | 1.2B | 1.1B |
| Cost of Goods Sold | 308.1M | 311.4M | 338.1M | 320.6M | 304.4M |
| Gross Profit | 1.2B | 1.1B | 1.0B | 916.7M | 784.3M |
| Gross Margin % | 79.6% | 78.0% | 75.2% | 74.1% | 72.0% |
| Operating Expenses | |||||
| Research & Development | 4.3M | 12.3M | 12.3M | 10.8M | 9.8M |
| Selling, General & Administrative | 156.9M | 165.0M | 167.2M | 231.7M | 218.7M |
| Other Operating Expenses | 183.1M | 172.0M | 156.5M | 37.4M | 36.1M |
| Total Operating Expenses | 344.4M | 349.4M | 336.0M | 279.9M | 264.7M |
| Operating Income | 376.8M | 307.8M | 281.1M | 253.6M | 178.1M |
| Operating Margin % | 24.9% | 21.7% | 20.6% | 20.5% | 16.4% |
| Non-Operating Items | |||||
| Interest Income | 52.6M | 41.3M | 40.2M | 43.7M | 40.5M |
| Interest Expense | 3.8M | 2.3M | 3.0M | 3.5M | 4.2M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 439.3M | 351.8M | 328.6M | 298.7M | 216.4M |
| Income Tax | 118.7M | 92.0M | 82.6M | 75.7M | 51.4M |
| Effective Tax Rate % | 27.0% | 26.2% | 25.1% | 25.4% | 23.7% |
| Net Income | 320.6M | 259.8M | 246.1M | 223.0M | 165.0M |
| Net Margin % | 21.2% | 18.3% | 18.1% | 18.0% | 15.2% |
| Key Metrics | |||||
| EBITDA | 461.8M | 376.0M | 352.4M | 318.2M | 240.9M |
| EPS (Basic) | ₹72.65 | ₹58.86 | ₹53.90 | ₹48.58 | ₹35.96 |
| EPS (Diluted) | ₹72.65 | ₹58.86 | ₹53.90 | ₹48.58 | ₹35.96 |
| Basic Shares Outstanding | 4413300 | 4413300 | 4565673 | 4589378 | 4589378 |
| Diluted Shares Outstanding | 4413300 | 4413300 | 4565673 | 4589378 | 4589378 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Jenburkt Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 73.6M | 41.3M | 36.6M | 50.3M | 24.9M |
| Short-term Investments | 157.8M | 698.4M | 458.2M | 415.5M | 495.1M |
| Accounts Receivable | 207.4M | 194.8M | 169.6M | 152.1M | 140.0M |
| Inventory | 88.8M | 85.6M | 83.4M | 98.9M | 75.8M |
| Other Current Assets | 16.6M | 14.3M | 1.4M | 60.0K | 11.7M |
| Total Current Assets | 565.3M | 1.1B | 810.9M | 759.0M | 799.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 144.3M | 99.7M | 102.6M | 110.9M | 100.7M |
| Goodwill | 2.3M | 3.9M | 1.9M | 3.1M | 4.8M |
| Intangible Assets | 2.3M | 3.9M | 1.9M | 3.1M | 4.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 27.7M | 254.6M | 120.2M | 113.1M | 910.0K |
| Total Non-Current Assets | 1.4B | 557.1M | 607.6M | 670.4M | 412.0M |
| Total Assets | 2.0B | 1.7B | 1.4B | 1.4B | 1.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 81.6M | 62.6M | 61.0M | 71.1M | 45.9M |
| Short-term Debt | 24.0M | 0 | 29.3M | 62.7M | 41.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 16.9M | 16.3M | 11.5M | 11.5M | 10.6M |
| Total Current Liabilities | 188.2M | 163.8M | 157.6M | 212.8M | 179.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 14.9M | - | 0 | 4.9M | 9.4M |
| Deferred Tax Liabilities | 10.9M | 7.9M | 7.2M | 8.6M | 8.2M |
| Other Non-Current Liabilities | - | - | -1.0K | - | -1.0K |
| Total Non-Current Liabilities | 55.9M | 37.8M | 36.6M | 42.9M | 47.2M |
| Total Liabilities | 244.1M | 201.6M | 194.2M | 255.7M | 227.2M |
| Equity | |||||
| Common Stock | 44.1M | 44.1M | 44.1M | 45.9M | 45.9M |
| Retained Earnings | 1.6B | 1.3B | 1.1B | 1.1B | 909.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.7B | 1.4B | 1.2B | 1.2B | 984.7M |
| Key Metrics | |||||
| Total Debt | 38.9M | 0 | 29.3M | 67.5M | 50.7M |
| Working Capital | 377.1M | 933.5M | 653.3M | 546.2M | 620.0M |
Balance Sheet Composition
Jenburkt Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 320.6M | 259.8M | 246.1M | 223.0M | 165.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -19.9M | -190.3M | -50.7M | -127.7M | 80.4M |
| Operating Cash Flow | 252.8M | 31.2M | 159.1M | 56.1M | 209.5M |
| Investing Activities | |||||
| Capital Expenditures | -197.1M | -25.5M | -21.0M | -25.5M | -11.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -1.9B | -1.5B | -853.8M | -1.3B | -1.1B |
| Investment Sales | 1.9B | 1.5B | 885.7M | 1.3B | 885.5M |
| Investing Cash Flow | -225.0M | -61.1M | 10.8M | -62.8M | -225.9M |
| Financing Activities | |||||
| Share Repurchases | - | 0 | -145.2M | 0 | - |
| Dividends Paid | -67.8M | -63.2M | -55.0M | -46.8M | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -67.8M | -63.2M | -200.1M | -46.8M | 1.4M |
| Free Cash Flow | 81.9M | 55.7M | 149.5M | 62.2M | 183.1M |
| Net Change in Cash | -40.0M | -93.1M | -30.3M | -53.5M | -15.0M |
Cash Flow Trend
Jenburkt Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.42
Forward P/E
30.41
Price to Book
2.56
Price to Sales
2.83
PEG Ratio
-0.38
Profitability Ratios
Profit Margin
19.63%
Operating Margin
15.33%
Return on Equity
18.66%
Return on Assets
16.34%
Financial Health
Current Ratio
3.00
Debt to Equity
0.93
Beta
0.33
Per Share Data
EPS (TTM)
₹73.50
Book Value per Share
₹414.40
Revenue per Share
₹374.21
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| JENBURPH | 4.7B | 14.42 | 2.56 | 18.66% | 19.63% | 0.93 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





